Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (14520)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 16, 2015 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Matsuoka T, Yashiro M. Recent advances in the HER2 targeted therapy of gastric cancer. World J Clin Cases 2015; 3(1): 42-51 [PMID: 25610849 DOI: 10.12998/wjcc.v3.i1.42] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v3/i1/42.htm |
| Number | Citing Articles |
| 1 |
Juan‐Cheng Yang, Ning Chang, Deng‐Chyang Wu, Wei‐Chung Cheng, Wei‐Min Chung, Wei‐Chun Chang, Fu‐Ju Lei, Chung‐Jung Liu, I‐Chen Wu, Hsueh‐Chou Lai, Wen‐Lung Ma. Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer. Journal of Cellular and Molecular Medicine 2019; 23(11): 7417 doi: 10.1111/jcmm.14605
|
| 2 |
Yung-Yu Hsieh, Shui-Yi Tung, Hung-Yu Pan, Chih-Wei Yen, Huang-Wei Xu, Yi-Fang Deng, Ying-Jhen Lin, Wan-Ting Hsu, Cheng-Shyong Wu, Chin Li. Upregulation of bone morphogenetic protein 1 is associated with poor prognosis of late-stage gastric Cancer patients. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4383-9
|
| 3 |
Wen‐Lung Ma, Ning Chang, Yingchun Yu, Yu‐Ting Su, Guan‐Yu Chen, Wei‐Chung Cheng, Yang‐Chang Wu, Ching‐Chia Li, Wei‐Chun Chang, Juan‐Cheng Yang. Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth. Cancer Medicine 2022; 11(14): 2824 doi: 10.1002/cam4.4536
|
| 4 |
Ewa Marcinkowska, Elżbieta Gocek. Resistance to Tyrosine Kinase Inhibitors. Resistance to Targeted Anti-Cancer Therapeutics 2016; : 1 doi: 10.1007/978-3-319-46091-8_1
|
| 5 |
D. L. Rotin, O. V. Paklina, I. O. Tin’kova, D. N. Grekov, G. R. Setdikova. CURRENT POINT OF VIEW ON PROGNOSTIC AND PREDICTIVE ROLES AND PRACTICAL APPLICATION OF HER2 RECEPTOR’S DETECTION. LITERATURE REVIEW. Russian Journal of Biotherapy 2020; 19(2): 6 doi: 10.17650/1726-9784-2019-19-2-6-12
|
| 6 |
Hiroki Irie, Kimihiro Ito, Yayoi Fujioka, Kei Oguchi, Akio Fujioka, Akihiro Hashimoto, Hirokazu Ohsawa, Kenji Tanaka, Kaoru Funabashi, Hikari Araki, Yuichi Kawai, Tadashi Shimamura, Renu Wadhwa, Shuichi Ohkubo, Kenichi Matsuo. TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Molecular Cancer Therapeutics 2019; 18(4): 733 doi: 10.1158/1535-7163.MCT-18-1085
|
| 7 |
Lucas Faria Abrahao-Machado, Cristovam Scapulatempo-Neto. HER2 testing in gastric cancer: An update. World Journal of Gastroenterology 2016; 22(19): 4619-4625 doi: 10.3748/wjg.v22.i19.4619
|
| 8 |
Marta Smolińska, Dariusz Grzanka, Paulina Antosik, Anna Kasperska, Izabela Neska-Długosz, Jakub Jóźwicki, Anna Klimaszewska-Wiśniewska. HER2, NF-κB, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation with Clinical and Pathological Parameters. Disease Markers 2019; 2019: 1 doi: 10.1155/2019/6315936
|
| 9 |
Hanaa Amrani Hassani Joutei, Nabila Marchoudi, Wafaa Mahfoud, Ilham Sadaoui, Taoufiq Fechtali, Hakima Benomar. Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients. Arab Journal of Gastroenterology 2018; 19(4): 155 doi: 10.1016/j.ajg.2018.08.001
|
| 10 |
Tasuku Matsuoka, Masakazu Yashiro. Biomarkers of gastric cancer: Current topics and future perspective. World Journal of Gastroenterology 2018; 24(26): 2818-2832 doi: 10.3748/wjg.v24.i26.2818
|
| 11 |
Shadi A. Esfahani, Carolina de Aguiar Ferreira, Nicholas J. Rotile, Bahar Ataeinia, Shriya Krishna, Onofrio A. Catalano, Peter Caravan, Yi-Fen Yen, Pedram Heidari, Umar Mahmood. HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer. Molecular Imaging and Biology 2023; 25(2): 353 doi: 10.1007/s11307-022-01763-9
|
| 12 |
Shuyi Cen, Meiqin Yuan, Qunan Sun, Guilan Hou, Jieer Ying, Qi Xu, Yu Zheng, Ying Dong, Hongming Pan, Weidong Han. Efficacy and safety of dual blockade of HER2 and PD-1 in patients with HER2-positive gastric cancer: a retrospective, multicentre study. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-76296-y
|
| 13 |
Carmen S. M. Yong, Janelle Sharkey, Belinda Duscio, Ben Venville, Wei-Zen Wei, Richard F. Jones, Clare Y. Slaney, Gisela Mir Arnau, Anthony T. Papenfuss, Jan Schröder, Phillip K. Darcy, Michael H. Kershaw, John P. Lydon. Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene. PLOS ONE 2015; 10(9): e0136817 doi: 10.1371/journal.pone.0136817
|
| 14 |
Takahiro Sato, Motonobu Saito, Shotaro Nakajima, Katsuharu Saito, Masanori Katagata, Satoshi Fukai, Hirokazu Okayama, Wataru Sakamoto, Zenichiro Saze, Tomoyuki Momma, Kosaku Mimura, Koji Kono. ARID1A deficiency is targetable by AKT inhibitors in HER2-negative gastric cancer. Gastric Cancer 2023; 26(3): 379 doi: 10.1007/s10120-023-01373-6
|
| 15 |
Yunyun Pan, Zhengyang Yang, Yuping Xu, Zhicheng Bai, Donghui Pan, Runlin Yang, Lizhen Wang, Wenxian Guan, Min Yang. Targeting HER2-positive gastric cancer with a novel 18F-labeled ZHER2:342 probe. RSC Advances 2019; 9(19): 10990 doi: 10.1039/C8RA10271F
|
| 16 |
Yonghui Zheng, Guoshuang Shen, Chengrong Zhang, Xingfa Huo, Yuanfang Xin, Qianqian Fang, Yumei Guan, Fuxing Zhao, Dengfeng Ren, Zhen Liu, Miaozhou Wang, Jiuda Zhao. Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis. Clinical and Experimental Medicine 2023; 23(7): 3205 doi: 10.1007/s10238-023-01072-7
|
| 17 |
Dhananjay Shukla, Saurabh Saxena, Pranav Kumar Prabhakar. Novel therapeutic approaches for gastrointestinal malignancies. Diagnostics and Therapeutic Advances in GI Malignancies 2020; : 115 doi: 10.1007/978-981-15-5471-1_8
|
| 18 |
Yuko T. Sato, Kaori Umezaki, Shinichi Sawada, Sada-atsu Mukai, Yoshihiro Sasaki, Naozumi Harada, Hiroshi Shiku, Kazunari Akiyoshi. Engineering hybrid exosomes by membrane fusion with liposomes. Scientific Reports 2016; 6(1) doi: 10.1038/srep21933
|
| 19 |
Hiroki Irie, Rumi Kawabata, Yayoi Fujioka, Fumio Nakagawa, Hiraku Itadani, Hideki Nagase, Kimihiro Ito, Junji Uchida, Shuichi Ohkubo, Kenichi Matsuo. Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728. Cancer Science 2020; 111(6): 2123 doi: 10.1111/cas.14407
|
| 20 |
Sumi Yun, Jiwon Koh, Soo Kyung Nam, Jung Ok Park, Sung Mi Lee, Kyoungyul Lee, Kyu Sang Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Gheeyoung Choe, Woo Ho Kim, Hye Seung Lee. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients. Gastric Cancer 2018; 21(2): 225 doi: 10.1007/s10120-017-0732-7
|
| 21 |
Gayatri Gouda, Manoj Kumar Gupta, Ravindra Donde, Lambodar Behera, Ramakrishna Vadde. Immunotherapy for Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies 2020; : 97 doi: 10.1007/978-981-15-6487-1_7
|
| 22 |
Yang-Kun Wang, Su-Nan Wang, Ying-Ying Li, Gong-Ping Wang, Tian Yun, Chao-Ya Zhu, Bin-Feng Yang, Cong-Yang Li, Bo Jiang, Mei-Ling Zhu. Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer. Cancer Biomarkers 2018; 21(2): 439 doi: 10.3233/CBM-170671
|
| 23 |
Shigenobu Motoshima, Koji Yonemoto, Hideki Kamei, Michi Morita, Rin Yamaguchi. Prognostic implications of HER2 heterogeneity in gastric cancer. Oncotarget 2018; 9(10): 9262 doi: 10.18632/oncotarget.24265
|
| 24 |
Shuyi Cen, Haimiao Xu, Zhen Liu, Rongjie Zhao, Hongming Pan, Weidong Han. Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer. Clinical and Experimental Immunology 2022; 207(3): 318 doi: 10.1093/cei/uxac007
|
| 25 |
Shota Fukuoka, Yoshikatsu Koga, Mayumi Yamauchi, Shigehiro Koganemaru, Masahiro Yasunaga, Kohei Shitara, Toshihiko Doi, Takayuki Yoshino, Toshio Kuronita, Brian Elenbaas, Pamela Wahra, Hong Zhang, Lindsey Crowley, Molly H. Jenkins, Anderson Clark, Takashi Kojima. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-40612-9
|
| 26 |
Aaron C. Tan, David L. Chan, Wasek Faisal, Nick Pavlakis. New drug developments in metastatic gastric cancer. Therapeutic Advances in Gastroenterology 2018; 11 doi: 10.1177/1756284818808072
|
| 27 |
Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, Simon Heeke, Paul Hannetel, Pierre Capela-Brosseau-Laborde, Charles-Hugo Marquette, Marius Ilié, Paul Hofman. Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches. Journal of Personalized Medicine 2022; 12(10): 1651 doi: 10.3390/jpm12101651
|
| 28 |
L Liang, J-Y Fang, J Xu. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene 2016; 35(12): 1475 doi: 10.1038/onc.2015.209
|
| 29 |
Jie Sun, Junjie Piao, Nan Li, Yang Yang, Ki‐Yeol Kim, Zhenhua Lin. Valproic acid targets HDAC1/2 and HDAC1/PTEN/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer. The FEBS Journal 2020; 287(10): 2118 doi: 10.1111/febs.15122
|
| 30 |
Shuyi Cen, Zhen Liu, Hongming Pan, Weidong Han. Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2021; 1876(2): 188605 doi: 10.1016/j.bbcan.2021.188605
|
| 31 |
Georgios D Lianos, Alberto Mangano, William C Cho, Dimitrios H Roukos. From standard to new genome-based therapy of gastric cancer. Expert Review of Gastroenterology & Hepatology 2015; 9(8): 1023 doi: 10.1586/17474124.2015.1060856
|
| 32 |
Yajun Zhang, Lingfei Wang, Xiaodan Chong, Xiaojie Yu, Yanchun Meng, Jian Dong, Chao Wang, Huajing Wang, Yang Yang, Tian Xia, Jian Zhao, Bohua Li. A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth. Biochemical and Biophysical Research Communications 2016; 477(4): 755 doi: 10.1016/j.bbrc.2016.06.131
|
| 33 |
Yukio Nagasaki. Design and application of redox polymers for nanomedicine. Polymer Journal 2018; 50(9): 821 doi: 10.1038/s41428-018-0054-6
|
| 34 |
Yunhan Sun, Shun Zhang, Yukai Shen, Haoyang Lu, Xincan Zhao, Xin Wang, Yongkai Wang, Taiping Wang, Bing Liu, Lan Yao, Jie Wen. Therapeutic application of mesenchymal stem cell-derived exosomes in skin wound healing. Frontiers in Bioengineering and Biotechnology 2024; 12 doi: 10.3389/fbioe.2024.1428793
|
| 35 |
V. Kunene, M. Ding, M. Yap, E.A. Griffiths, P. Taniere, D. Fackrell, S. Butler, G. Contino. Prognostic markers in oesophageal and gastric cancer review. Are they ready for clinical practice?. ESMO Gastrointestinal Oncology 2024; 6: 100091 doi: 10.1016/j.esmogo.2024.100091
|
| 36 |
Zhaohui Jin, Harry H. Yoon. Antiangiogenic Therapy in Gastroesophageal Cancer. Hematology/Oncology Clinics of North America 2017; 31(3): 499 doi: 10.1016/j.hoc.2017.01.008
|
| 37 |
Shadi A. Esfahani, Cody Callahan, Nicholas J. Rotile, Pedram Heidari, Umar Mahmood, Peter D. Caravan, Aaron K. Grant, Yi-Fen Yen. Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer. Molecular Imaging and Biology 2022; 24(5): 769 doi: 10.1007/s11307-022-01727-z
|